Biosimilar Interchangeability Reform

Summary#

This bill removes the separate federal "interchangeable" determination for biosimilar biological products and makes most biosimilars automatically interchangeable with their reference product after a short transition period. Its stated aim is to reduce regulatory steps that the bill’s title calls "red tape" and to simplify market entry for biosimilars.

• Main change: Biosimilars licensed under the federal biosimilar pathway will be deemed interchangeable with the reference product either on licensure or 60 days after the bill becomes law, with a narrow exception to protect already-issued exclusivity periods.
• Transition rule: The bill sets a 60‑day transition date after enactment when the automatic interchangeability takes effect for products licensed before that date.
• Exclusivity protection: If a biosimilar or biologic already has an unexpired "first interchangeable exclusivity" period in effect on enactment, that exclusivity remains in force until it expires. New automatic interchangeability is delayed where that exclusivity applies.
• Statutory cleanup: The bill edits federal statutes to remove separate references to "interchangeable" biosimilars and updates related legal language.
• FDA guidance: The FDA must update or revoke prior guidance documents and issue revised guidance about biosimilarity and interchangeability within set deadlines (generally within 18 months).

What it means for you#

• Manufacturers of biosimilars

  • This could mean you no longer need to submit separate interchangeability data (such as switching studies) to obtain a federal interchangeability label for most future biosimilars.
  • You may be able to bring products to market faster and with lower development cost if switching-study requirements are effectively removed.
  • If you already hold an exclusivity period for being the first interchangeable product, that exclusivity is preserved until it expires.

• Manufacturers of reference biologics (brand makers)

  • The value of a future "first interchangeable" exclusivity may be reduced, because interchangeability will be automatic for most new biosimilars.
  • Existing exclusivity periods for products licensed before enactment are preserved until they expire.

• Pharmacists

  • This could make it easier to substitute a biosimilar for a prescribed reference biologic in states whose laws allow substitution based on an FDA interchangeability finding. State substitution rules vary, so immediate effect will depend on state law.

• Patients

  • Could increase the chance that a patient receives a biosimilar product in place of a reference biologic where substitution is allowed.
  • The bill does not change clinical care rules directly. Switching decisions may still be guided by clinical judgment and state pharmacy law.

• Insurers and payers

  • Could have more options for contracting or preferred-product lists, potentially increasing use of biosimilars.

• FDA and federal agencies

  • The FDA must revise or revoke existing interchangeability guidance and issue new guidance within the bill’s deadlines. This requires staff time and rule-writing work.

Expenses#

No publicly available information on a formal cost estimate or fiscal note is included in the bill text or accompanying material.

• The FDA will incur administrative and staff costs to update and reissue guidance documents within the timelines set by the bill.
• Manufacturers may save on the costs of conducting additional clinical switching studies that are typically part of an interchangeability application. The bill itself does not quantify those savings.
• Any downstream changes in health-care spending (for example, due to greater biosimilar uptake and potential price effects) are not estimated in the available materials.

Proponents' View#

• The bill appears intended to remove what it calls duplicative regulatory steps that delay access to biosimilars.
• A possible argument for the bill is that making biosimilars automatically interchangeable will speed patient access and increase competition in biologic markets.
• Supporters may argue this reduces the need for extra switching studies, lowering development costs for biosimilar manufacturers.
• Requiring FDA guidance updates could clarify the review pathway and remove conflicting or outdated guidance documents.

Opponents' View#

• One concern is that removing the separate interchangeability standard could eliminate the specific clinical switching evidence (switching studies) that some view as important to show safety and effectiveness when patients switch between products.
• The bill does not fully explain how automatic interchangeability will interact with diverse state pharmacy substitution laws. State rules vary, so substitution at the pharmacy level may not be uniform across the country.
• By making interchangeability automatic for future biosimilars, the bill could weaken the commercial incentive represented by first interchangeable exclusivity for future applicants. How that affects innovation and investment is not quantified.
• It may create a patchwork where some products remain effectively non-interchangeable while others are automatically interchangeable depending on existing exclusivity periods. The practical handling of those timing and exclusivity interactions is not fully detailed in the bill.
• The bill requires FDA guidance updates but does not include a fiscal estimate of the agency’s costs or specify implementation details for how FDA will transition from existing guidance.

What is unclear from the available material: the bill text does not provide a fiscal estimate, and it leaves some implementation questions—especially how automatic interchangeability will operate across different state substitution laws and how FDA will handle products that relied on other biosimilars rather than directly on the reference product.